Simultaneous Determination of Metronidazole and Diiodohydroxyquine in Bulk Powder and Paramibe Compound Tablets by TLC-Densitometry and HPLC

Hesham Salem1, Safaa M. Riad2, Mamdouh R. Rezk2 and Kholoud Ahmed2*

1Pharmaceutical and Analytical Chemistry Department, Faculty of Pharmacy, October University for Modern Sciences and Arts, 6th of October city, Egypt
2Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, 11562 Cairo, Egypt

Abstract

Two sensitive and precise chromatographic methods were developed and validated for simultaneous determination of metronidazole (MTR) and diiodohydroxyquin (DIQ) in pharmaceutical preparations. The techniques adopted for quantification are coupled TLC-densitometry and HPLC. A mixture of chloroform, toluene, ethanol and acetic acid (9:9:1:1, v/v/v/v) was used as the developing solvent for TLC-densitometry. A mixture of methanol and acetonitrile, (96:4, v/v) was used as a mobile phase for HPLC at 0.6 mL min⁻¹ flow rate and UV detection at 254 nm. Linearity was obtained in concentration range of 0.5-10 µg spot⁻¹ for DIQ and 1-20 µg spot⁻¹ for MTR applying TLC-densitometry and 0.005-0.5 mg mL⁻¹ for DIQ and 0.01-0.5 mg mL⁻¹ for MTR applying HPLC. The selectivity of the proposed methods was checked using laboratory prepared mixtures. The proposed methods were successfully applied to the analysis of MTR and DIQ in their mixture and in pharmaceutical dosage forms without interference from other additives.

Keywords: Metronidazole; Diiodohydroxyquinoline; TLC-Densitometry; HPLC; Tablets dosage form

Introduction

Metronidazole (MTR), is 2-(2-methyl-5-nitro-1H-imidazol-1-yl) ethanol (Figure 1a). It is used as antibacterial and antiamoebiasis [1]. Metronidazole is metabolized by oxidation to 2-hydroxymethyl metronidazole and 2-methyl-5-nitroimidazol-1-acetic acid, and by conjugation with glucuronic acid. About 70 to 80% of a dose is excreted in the urine in 48 hr with less than 10% of the dose as unchanged drug, up to 10% as conjugated MTR, about 27% as 2-hydroxymethylmetronidazole, 10% as the conjugated 2-hydroxymethyl metabolite, and 20% as the acid metabolite [2]. Diiodohydroxyquinoline (DIQ), 5,7-diiodoquinolin-8-ol (Figure 1b). It is widely known by the trade name Diodoquin, is a quinoline derivative which can be used in the treatment of amoebiasis. Iodoquinol is poorly absorbed from the gastrointestinal tract and is amebicidal at the site of infection. It acts by chelating ferrous ions essential for metabolism [3].

The literature survey reveals several analytical methods for quantitative estimation of MTR in body fluids and in pharmaceutical formulations these methods include ultraviolet spectrophotometry [4-6], high-performance liquid formulations (HPLC) [7,8] and voltammetry [9]. Quantitation of metronidazole and spiramycin in human plasma, saliva and gingival crevicular fluid by LC–MS/MS [10]. Simultaneous multi residue determination of metronidazole and spiramycin in fish muscle using high performance liquid chromatography with UV detection [11]. Microsized Graphite Sensors for potentiometric determination of metronidazole and spiramycin [12]. DIQ was determined in pharmaceutical formulations using HPLC [13].

The present work aimed to develop simple instrumental methods for simultaneous determination of MTR and DIQ in combination. These methods include as chromatographic methods; namely, TLC-densitometry method and HPLC [14].

Experimental

Instruments

Camag TLC scanner 3S/N 130319 with winCATS software. Camag

Figure 1a: Chemical structure of Metronidazole (MTR).

Figure 1b: Chemical structure of Diiodohydroxyquine (DIQ).
linomat autosampler (Switzerland), Camag microsyringe (100 µL). A liquid chromatography consisted of a quaternary pump (Agilent Model G1316/G1316B), a diode array multiple wavelength detector (Model G1316 C/D and G1365C/D, Agilent 1200 Series), standard and preparation autosamplers (Agilent 1200 series) equipped vacuum degasser, Agilent. Stationary phase (250 mm×4.6 mm, 10 µm) C_{18} Lichrosorb™ 10 µm analytical column, Alltech (USA). Mobile phase; methanol and acetonitrile (96:4, v/v) isocratically at 0.6 mL min⁻¹. The mobile phase was filtered through a 0.45 µm millipore membrane filter and was degassed for ~15 min in an ultrasonic bath prior to use. UV-detection was done at 254 nm. The samples were filtered also through a 0.45 µm membrane filter.

**Solvents, authentics and pharmaceutical preparation**

Reference metronidazole hydrochloride powder (MTR) and reference diiodohydroxyque (DIQ) were kindly donated by Al Qahir Pharmaceuticals Co. The potency was found to be 1002 µg mg⁻¹. Pharmaceutical dosage form (Paramibe compound, 500 mg tablets) were kindly supplied by Chemical Industries Development (CID) and Qahir Pharmaceuticals Co. The potency was found to be 1002 µg mg⁻¹. Pharmaceutical dosage form (Paramibe compound, 500 mg tablets) were kindly supplied by Chemical Industries Development (CID) and Qahir Pharmaceuticals Co. The potency was found to be 1002 µg mg⁻¹.

**MTR standard solution and DIQ standard solution (0.5 mg mL⁻¹ each) in mobile phase for the HPLC method and MTR standard solution (1 mg mL⁻¹) and DIQ (0.5 mg mL⁻¹) in methanol for TLC-densitometric method. The standard solutions were freshly prepared on the day of analysis and stored in a refrigerator to be used within 24 hr.

**Procedures**

### TLC-densitometric method:

- **Linearity:** Aliquots 1-20 µL of MTR standard solution (1 mg mL⁻¹) and DIQ (0.5 mg mL⁻¹) were applied in the form of bands on a TLC plate. The band length was 4 mm apart from each other and 10 mm from the bottom edge of the plate. Linear ascending development was performed in a chromatographic tank previously saturated with chloroform, toluene, ethanol and acetic acid (9:9:1:1, v/v/v/v) for 1 hr at room temperature. The developed plates were air-dried and scanned at 311 nm using deuterium lamp, absorbance mode at 3 mm×0.45 mm slit dimension and scanning speed of 20 mms⁻¹. Calibration curves relating the optical density of each spot to the corresponding concentration of MTR and DIQ were constructed. The regression equations were then computed for the studied drugs and used for determination of unknown samples containing them (Table 2).

### Liquid chromatographic method:

- **Linearity**: Portions 0.1–2 mL from MTR standard solution (0.5 mg mL⁻¹ in the mobile phase) and DIQ (0.5 mg mL⁻¹) were transferred separately into a series of 10-mL volumetric flasks and completed with mobile phase. The contents of each flask were completed to volume with the mobile phase to get the concentrations of 5–1000 mg mL⁻¹ of MTR and 5-500 mg mL⁻¹ of DIQ. The samples were then chromatographed using the following chromatographic condition. Stationary phase (250 mm×4.6 mm 10 µm) C_{18} Lichrosorb™ 10 µm analytical column, Alltech (USA), mobile phase; methanol and acetonitrile, (96:4, v/v). The mobile phase was filtered through a 0.45 µm millipore membrane filter and was degassed for about 15 min in an ultrasonic bath prior to use, flow rate; 0.6 mL min⁻¹ [isocratically at ambient temperature (~25°C)], with UV-detection at 254 nm. The samples were filtered also through a 0.45 µm membrane filter. To reach good equilibrium, the analysis was usually performed after passing ~50–60 mL of the mobile phase, just for conditioning and pre-washing of the stationary phase. The relative peak area ratios (by using 0.04 mg mL⁻¹ MTR and 0.0375 mg mL⁻¹ DIQ as divisor) were then plotted versus the corresponding concentrations of MTR and DIQ to get the calibration graphs and to compute the corresponding regression equations. Concentrations of unknown samples of MTR and DIQ were determined using the obtained regression equations.

### Analysis of laboratory prepared mixtures containing different ratios of MTR and DIQ:

Aliquots were mixed to prepare different mixtures containing different ratios (1:1, 1:4, 1:3, 2:1) of MTR and DIQ.

### Table 1: Assay parameters and validation sheet for determination of metronidazole (MTR) and diiodohydroxyquine (DIQ).

| Parameter | TLC-densitometric method | HPLC method |
|-----------|--------------------------|-------------|
| Range     | MTR                     | DIQ         | MTR                  | DIQ          |
|           | 1-20 µg spot⁻¹           | 0.5-10 µg spot⁻¹ | 0.01-1 mg mL⁻¹       | 0.005-0.5 mg mL⁻¹ |
| Slope     | 0.079                    | 0.438       | 39.69                | 38.16        |
| Intercept | 0.092                    | 0.738       | 99.92                | 100.15       |
| Mean      | 99.87                    | 100.15      | 99.87                | 100.15       |
| ± S.D.    | 0.365                    | 0.592       | 0.433                | 0.483        |
| Variance  | 0.133                    | 0.352       | 0.187                | 0.233        |
| Coefficient of variation | 0.365           | 0.592       | 0.433                | 0.482        |
| Correlation coefficient (r) | 0.9999     | 0.9999     | 0.9999               | 0.9999       |
| R.S.D. (%) | 0.365                    | 0.592       | 0.433                | 0.482        |

### Table 2: Determination of MTR and DIQ in paramibe compound tablet by proposed methods.

| Preparation               | TLC-densitometric method | HPLC method |
|---------------------------|--------------------------|-------------|
| Paramibe compound tablets (0.5 g) |                         |             |
| MTR mean ± S.D.           | 99.87 ± 0.165            | 99.995 ± 0.313 |
| DIQ mean ± S.D.           | 99.61 ± 0.098            | 100.008 ± 0.121 |
DIQ, respectively. The concentrations were calculated from the corresponding regression equations (Table 3).

**Assay of pharmaceutical formulations (Paramibe compound tablets):** Twenty tablets were weighed and grinded to determine the average weight per tablet. Aliquot of the powder tablet equivalent to 250 mg of MTR and DIQ each was extracted by shaking with methanol for 15 minutes then the volume was completed to the mark with methanol to get a concentration of 1 mg mL\(^{-1}\) of MTR and DIQ and proceed as described under each method.

**Results and Discussion**

**TLC-fractionation**

TLC-monitoring of MTR and DIQ was done on thin layer plates of silica gel F254 using chloroform, toluene, ethanol and acetic acid (9:9:1:1, v/v/v/v) as the developing solvent. The developed plates were visualized under short UV-lamp. MTR (R\(_f\)=0.13) could be separated from DIQ (R\(_f\)=0.741).

**Chromatographic methods**

TLC-densitometry: A TLC-densitometric method is described for the determination of MTR in the presence of DIQ without prior separation. Different solvent systems were tried for the separation of MTR and DIQ. Satisfactory results were obtained by using a mobile phase composed of chloroform, toluene, ethanol and acetic acid (9:9:1:1, v/v/v/v), where R\(_f\)=0.13 and 0.740 for MTR and DIQ, respectively. The separation allows the determination of MTR with no interference from DIQ (Figure 4). The linearity was confirmed by plotting the measured peak area versus the corresponding concentrations at 311 nm over a range of 1–20 µg spot\(^{-1}\) and 0.5–10 µg spot\(^{-1}\) for MTR and DIQ, respectively where a linear response was obtained (Figures 2 and 3). The regression equation was found to be: A=0.079C+0.092, r=0.9998; for MTR \(\mathrm{mg}\ \mathrm{mL}^{-1}\) and r is the correlation coefficient and for DIQ, the regression equation was found to be: A\(_2\)=0.438C\(_2\)+0.738, r\(_2\)=0.9999; where A\(_2\) is the area under the peak and C\(_2\) is the concentration of DIQ in µg spot\(^{-1}\) and r\(_2\) is the correlation coefficient (Table 4).

The precision of the proposed method was checked by the analysis of different concentrations of authentic samples in triplicates. The

| Substance | TLC-densitometric method (Mean ± SD) | HPLC method (Mean ± SD) |
|-----------|--------------------------------------|--------------------------|
| MTR       | 100.10 ± 0.469                       | 100.28 ± 0.085           |
| DIQ       | 100.28 ± 0.085                       | 100.28 ± 0.085           |

Table 3: Determination of metronidazole and diiodohydroxyquine in laboratory prepared mixtures by the proposed methods.

**Figure 2:** Linearity of MTR (1-20) µg spot\(^{-1}\) (R\(_f\)=0.13) DIQ (0.5-10) µg spot\(^{-1}\) (R\(_f\)=0.74) measured at 311 nm.

**Figure 3:** Separation of MTR (R\(_f\)=0.13) from DIQ (R\(_f\)=0.74) upon using chloroform+toluene+ethanol+acetic acid (9:9:1:1, v/v/v/v).

**Figure 4:** Separation of MTR (R\(_f\)=0.13) from DIQ (R\(_f\)=0.74).

**Figure 5:** Liquid chromatographic separation of metronidazole (2.344 min) and diiodohydroxyquine (3.548 min) upon using methanol+acetonitrile, (96:4, v/v) as a mobile phase.
mean percentage recovery was found to be 99.87 ± 0.365 for MTR and 100.15 ± 0.539 for DIQ (Table 1).

High-performance liquid chromatography: A simple isocratic high-performance liquid chromatographic method was developed for the determination of MTR and DIQ in pure form and in pharmaceutical preparation (250 mm×4.6 mm, 10 µm) C18 lichrosorb® analytical column. The mobile phase was consisting of methanol and acetonitrile, (96:4, v/v). The mobile phase was chosen after several trials to reach the optimum stationary/mobile-phase matching. The average retention times under the conditions described were 2.344 min for MTR, 3.548 min for DIQ (Figure 5). One sample can be chromatographed in less than 6 min. Peak purity was confirmed for the HPLC peaks of both MTR and DIQ by a pilot run using a photodiode array detector. Calibration graph was obtained by plotting the relative peak area ratios (by using 0.04 mg mL−1 MTR and 0.0375 mg mL−1 DIQ as divisor) against concentration of MTR and DIQ (mg mL−1). Linearity range was found to be 0.01–1 mg mL−1 for MTR and 0.005–0.5 mg mL−1 of DIQ. The regression equation for MTR: A = 39.69C−0.486 (r=0.9999) where A is the relative peak area ratio, C is the concentration of MTR (mg mL−1) and r is the correlation coefficient and for DIQ A = 38.16C2+0.011 (r=0.9999). The mean percentage recovery of pure sample was found to be 99.92 ± 0.433 for MTR and 100.15 ± 0.483 for DIQ (Table 1).

Conclusion
The suggested methods are found to be sensitive and precise. Application of the proposed methods to the analysis of MTR and DIQ in their pharmaceutical formulation shows that excipient do not interfere with the determination. The proposed methods can be used for routine analysis of metronidazole and diiodohydroxyquin in quality control laboratories.

References
1. British pharmacopoeia (2009) vol. I & II, pp.3952.
2. Galichet LY (2005) Clarke’s Analysis of Drugs and Poisons. (3rd edn), Pharmaceutical Press, London, UK.
3. Sweetman S (2005) Martindale: The complete drug reference, Pharmaceutical Press, London, UK.
4. Rehman AU, Ijaz AS, Raza A (2005) Spectrophotometric determination of metronidazole in pharmaceutical pure and dosage forms using p-benzoquinone. Journal of the Iranian Chemical Society 2: 197-202.
5. Siddappa K, Mallikarjun M, Reddy PT, Tambe M (2008) Spectrophotometric determination of metronidazole through Schiff’s base system using vanillin and PDAB reagents in pharmaceutical preparations. Eclet Quím 33.
6. Adeogoke OA, Umoh OE (2009) A new approach to the spectrophotometric determination of metronidazole and tinidazole using p-dimethylaminobenzaldehyde. Acta Pharm 59: 407-419.
7. Mustapha KB, Odunola MT, Garba M, Obodozie O (2006) Rapid, cost-effective liquid chromatographic method for the determination of metronidazole in biological fluids. Afr J Biotechnol 5: 1188-1191.
8. Cox S, Allender MC, Yarborough J (2009) Determination of metronidazole in adult artemia using high performance liquid chromatography. J Liq Chromatogr Relat Technol 33: 89-96.
9. Bartlett PN, Ghoneim E, El-Hefnawy G, El-Hallag I (2005) Voltammetry and determination of metronidazole at a carbon fiber microdisk electrode. Talanta 66: 869-874.
10. Sagan C, Salvador A, Dubreuil D, Poulet PP, Duffaut D, et al. (2005) Simultaneous determination of metronidazole and spiramycin I in human plasma, saliva and gingival crevicular fluid by LC–MS/MS. J Pharm Biomed Anal 38: 298-306.
11. Maher HM, Youssef RM, Khalil RH, El-Bahr SM (2008) Simultaneous multiresidue determination of metronidazole and spiramycin in fish muscle using high performance liquid chromatography with UV detection, J Chromatogr B Analyt Technol Biomed Life Sci 876: 175-181.
12. Khattab FI, Ramadan NK, Hegazy MA, Ghoniem NS (2011) Microsized Graphite Sensors for Potentiometric Determination of Metronidazole and Spiramycin. Portugaliae Electrochimica Acta 29: 79-90.
13. Gomaa ZS (1987) Determination of Diiodohydroxyquin in Dosage Forms by High Performance Liquid Chromatography. Journal of Liquid Chromatography 10: 1175-1185.
14. Spiegel M, Stephens L (1999) Schaum Outline of Theory and Problems of Statistics, Schaum Outline Series, NY, USA.